Is the Price Right for Aducanumab?

The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.GuestJohn A Galdo, PharmD, MBA, BCPS, BCGPCourse Content and Developer, CEimpactPharmacist, Ross Bridge PharmacyCEO, SeguridadRedeem your CPE or CME credit here!We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964References and resources: Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdfContinuing Education Information:Learning Objectives:1. Discuss the outcomes for phase III trials of aducanumab2. Define the cost-effectiveness of aducanumab0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-21-265-H01-PInitial release date: 7/27/21Expiration date: 7/27/22John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.Complete CPE & CME details can be found here.Follow CEimpact on Social Media:LinkedInInstagram